Results 51 to 60 of about 2,565,028 (307)

SensorShoe: Mobile Gait Analysis for Parkinson's Disease Patients [PDF]

open access: yes, 2007
We present the design and initial evaluation of a mobile gait analysis system, SensorShoe. The target user group is represented by Parkinson's Disease patients, which need continuous assistance with the physical therapy in their home environment ...
Havinga, P.J.M.   +3 more
core   +2 more sources

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]

open access: yes, 2016
Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D.   +8 more
core   +2 more sources

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

The stability analyses of the mathematical models of hepatitis C virus infection [PDF]

open access: yes, 2015
There are two mathematical models of Hepatitis C virus (HCV) being discussed; the original model of HCV viral dynamics (Neumann et al., 1998) and its extended model (Dahari et al., 2007). The key aspects of the mathematical models have provided resources
Chong, Maureen Siew Fang   +3 more
core   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

Target-specific glioma therapy in an immunocompetent mouse model : meeting abstract [PDF]

open access: yes, 2006
Objective: Establishment of an immunocompetent mouse model representing the typical progressive stages observed in malignant human gliomas for the in vivo evaluation of novel target-specific regimens.
Baus, Daniela   +7 more
core  

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation [PDF]

open access: yes, 2015
The acquisition of endocrine therapy resistance in estrogen receptor a (ERa) breast cancer patients represents a major clinical problem. Notch signalling has been extensively linked to breast cancer especially in patients who fail to respond to endocrine
Aifantis   +54 more
core   +3 more sources

Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation

open access: yesScientific Reports
Antisense oligonucleotides (ASOs) are synthetic single-stranded oligonucleotides that bind to RNAs through Watson–Crick base pairings. They are actively being developed as therapeutics for various human diseases.
Tokuyuki Yoshida   +12 more
doaj   +1 more source

Performance Comparison of Knowledge-Based Dose Prediction Techniques Based on Limited Patient Data. [PDF]

open access: yes, 2018
PurposeThe accuracy of dose prediction is essential for knowledge-based planning and automated planning techniques. We compare the dose prediction accuracy of 3 prediction methods including statistical voxel dose learning, spectral regression, and ...
Landers, Angelia   +4 more
core  

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

open access: yes, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena   +15 more
core   +2 more sources

Home - About - Disclaimer - Privacy